Letetresgene autoleucel (Lete-Cel (GSK3377794))

Phase 2Cell therapy

Letetresgene autoleucel (Lete-Cel (GSK3377794)) is one of 30 small molecule programs targeting Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeoplasmsCompleted

NeoplasmsPhase 2

Completed

Competition

Competitive Landscape

45 competitors in Neoplasms

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

1 2

Avastin

Roche

Phase 3

1 3

Taxol

Teva

Phase 3

1 4

Xtandi

Astellas

Phase 3

1 5

Alimta

SShawn Eagle

Phase 3

1 6

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 7

Fludara

Sanofi

Phase 2

3 8

Camptosar

Pfizer

Phase 2

1 9

Cyramza

Eli Lilly

Phase 2

1 10

Gemzar

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Neoplasms

NCT03967223

Clinical

Trials by Indication[1]

Neoplasms2 trials

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Completed·UUSWM CT, LLC·Phase 2·NCT06703346·82 enrolled

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Active, not recruiting·UUSWM CT, LLC·Phase 2·NCT03967223·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Letetresgene autoleucel (Lete-Cel (GSK3377794)). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letetresgene autoleucel (Lete-Cel (GSK3377794)) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letetresgene autoleucel (Lete-Cel (GSK3377794)). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — USWM CT, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: UUSWM CT, LLC

Letetresgene autoleucel (Lete-Cel (GSK3377794))

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Neoplasms2 trials

References

Drug Info

Quick Facts

Related News